Vivos Therapeutics (NASDAQ:VVOS) Coverage Initiated at HC Wainwright

Equities researchers at HC Wainwright initiated coverage on shares of Vivos Therapeutics (NASDAQ:VVOS) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 183.40% from the company’s previous close.

VVOS has been the subject of a number of other reports. Ascendiant Capital Markets raised their price target on shares of Vivos Therapeutics from $6.20 to $6.50 and gave the company a “buy” rating in a report on Tuesday, September 9th. Zacks Research cut shares of Vivos Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut Vivos Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 10th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $5.25.

Vivos Therapeutics Price Performance

Shares of NASDAQ VVOS opened at $2.47 on Monday. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.05 and a quick ratio of 1.05. Vivos Therapeutics has a 1-year low of $1.98 and a 1-year high of $7.95. The company has a market capitalization of $18.54 million, a price-to-earnings ratio of -1.47 and a beta of 6.88. The business has a 50-day moving average of $2.97 and a 200-day moving average of $3.52.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings results on Tuesday, August 19th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). The company had revenue of $3.82 million during the quarter, compared to analysts’ expectations of $3.37 million. Vivos Therapeutics had a negative return on equity of 232.76% and a negative net margin of 99.49%. On average, equities analysts anticipate that Vivos Therapeutics will post -1.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Vivos Therapeutics

A number of hedge funds have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in Vivos Therapeutics in the second quarter valued at about $65,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Vivos Therapeutics in the 2nd quarter worth approximately $220,000. Finally, Connective Capital Management LLC bought a new stake in shares of Vivos Therapeutics in the 3rd quarter valued at approximately $620,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.